The comparative safety of buprenorphine versus methadone in pregnancy-what about confounding?

Preferential treatment of high-risk opioid-dependent pregnant women with methadone limits evidence of the comparative safety of buprenorphine versus methadone on infant outcomes. Adjustment for maternal characteristics that affect both treatment choices and birth outcomes is necessary to provide valid estimates of the effect of prenatal opioid agonist therapy exposure.

[1]  H. Jones,et al.  Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta‐analysis of safety in the mother, fetus and child , 2016, Addiction.

[2]  M. Werler,et al.  Confounding of the Comparative Safety of Prenatal Opioid Agonist Therapy. , 2015, Journal of addiction research & therapy.

[3]  P. Sebastiani,et al.  Prenatal buprenorphine versus methadone exposure and neonatal outcomes: systematic review and meta-analysis. , 2014, American journal of epidemiology.

[4]  J. McAllister,et al.  Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. , 2012, JAMA.

[5]  Ursula A. Pritham,et al.  Opioid dependency in pregnancy and length of stay for neonatal abstinence syndrome. , 2012, Journal of obstetric, gynecologic, and neonatal nursing : JOGNN.

[6]  H. Bauchner,et al.  The Relationship Between Maternal Opioid Agonists and Psychiatric Medications on Length of Hospitalization for Neonatal Abstinence Syndrome , 2011, Journal of addiction medicine.

[7]  R. Jagsch,et al.  Impact of treatment approach on maternal and neonatal outcome in pregnant opioid‐maintained women , 2011, Human psychopharmacology.

[8]  A. Berrebi,et al.  Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study , 2011, European Journal of Clinical Pharmacology.

[9]  Onyebuchi A Arah,et al.  Bias Formulas for Sensitivity Analysis of Unmeasured Confounding for General Outcomes, Treatments, and Confounders , 2011, Epidemiology.

[10]  H. Jones,et al.  Neonatal abstinence syndrome after methadone or buprenorphine exposure. , 2010, The New England journal of medicine.

[11]  S. Hernández-Díaz,et al.  Antidepressant Use During Pregnancy and the Risk of Preterm Delivery and Fetal Growth Restriction , 2009, Journal of clinical psychopharmacology.

[12]  E. Ravndal,et al.  Opioid Maintenance Treatment during Pregnancy: Occurrence and Severity of Neonatal Abstinence Syndrome , 2009, European Addiction Research.

[13]  M. Heilig,et al.  Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. , 2008, Drug and alcohol dependence.

[14]  L. Simmat-Durand,et al.  Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. , 2006, Drug and alcohol dependence.

[15]  B. Lester,et al.  Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. , 2005, Drug and alcohol dependence.

[16]  H. Jones,et al.  Neonatal outcomes following in utero exposure to methadone or buprenorphine: a National Cohort Study of opioid-agonist treatment of Pregnant Women in Norway from 1996 to 2009. , 2013, Drug and alcohol dependence.